Divi's Laboratories Ltd

Divis Laboratories Ltd share price ticked higher by 2.76% to Rs 8056.65 after the company's net profit saw a strong growth of 20.11% to Rs 902.0 crore, while revenue from operations improved marginally 8.80% to Rs 3080.0 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 23.86 lakh crore, gaining 5.89%. It has marginally improved by 2.79% over last one week and rallied by 15.59% in last one month while the market capitalization of Divis Laboratories Ltd has edged up by 11.18% and 23.85% in the same period respectively. Profit before tax (PBT) of Divis Laboratories Ltd stood at Rs 1180.0 crore in Q2 FY26, rallying 60.98% year-on-year, and surging by 22.53% quarter-on-quarter. EBITDA came in at Rs 1191 crore, expanding by 95.25% YoY and jumping 52.89% sequentially. Total expenses marginally dropped 2.93% to Rs 1958.0 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 1503.0 crore, witnessing a sharp rise of 23.81% YoY, while employee benefits expense was at Rs 408.0 crore, rising by 7.09% YoY. For the TTM ended FY26, revenue from operations grew 12.82% to Rs 10560.0 crore, while net profit registered a growth of 17.21% to Rs 2568.0 crore, compared to previous TTM. EBITDA surged by 267600% to Rs 2934.0 crore, and PBT rose 16.19% to Rs 3388.0 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 2738.0 crore in FY26, as against Rs 1653.0 crore in FY25. Divis Laboratories Ltd soared by 22.06% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 3.81% during the same period.

Divis Laboratories Ltd rose for a fifth straight session today. The stock is quoting at Rs 8029, up 2.48% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.35% on the day, quoting at 24401.75. The Sensex is at 78214.53, up 0.37%. Divis Laboratories Ltd has added around 22.66% in last one month. Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has added around 5.81% in last one month and is currently quoting at 26346.05, up 1.14% on the day. The volume in the stock stood at 4.85 lakh shares today, compared to the daily average of 4.72 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 8044.5, up 2.37% on the day. Divis Laboratories Ltd is up 26.21% in last one year as compared to a 0.67% fall in NIFTY and a 21.06% fall in the Nifty Pharma index.The PE of the stock is 78.18 based on TTM earnings ending March 26.

Divi's Laboratories Limited informed the National Stock Exchange of India Limited and BSE Limited that L. Ramesh Babu and D. Madhu Babu will cease to be Senior Management Personnel, retiring from their positions as Vice President (Procurement) and Vice President (Projects) respectively, effective July 31, 2026.

Divis Laboratories Ltd gained for a third straight session today. The stock is quoting at Rs 7750.5, up 4.38% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.94% on the day, quoting at 24210.65. The Sensex is at 77537, up 1%. Divis Laboratories Ltd has risen around 17.81% in last one month. Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has risen around 3.98% in last one month and is currently quoting at 25998.85, up 1.29% on the day. The volume in the stock stood at 5.86 lakh shares today, compared to the daily average of 4.36 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 7772.5, up 4.24% on the day. Divis Laboratories Ltd is up 16.55% in last one year as compared to a 2.59% drop in NIFTY and a 14.13% drop in the Nifty Pharma index.The PE of the stock is 73.99 based on TTM earnings ending March 26.Powered by Capital Market - Live

Divis Laboratories will hold a meeting of the Board of Directors of the Company on 1 August 2026.

Divis Laboratories Ltd rose for a fifth straight session today. The stock is quoting at Rs 7296, up 1.5% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.45% on the day, quoting at 24160.1. The Sensex is at 77455.4, up 0.52%. Divis Laboratories Ltd has added around 8.69% in last one month. Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has added around 7.92% in last one month and is currently quoting at 25907.1, up 0.64% on the day. The volume in the stock stood at 4.33 lakh shares today, compared to the daily average of 3.82 lakh shares in last one month. The benchmark July futures contract for the stock is quoting at Rs 7265.5, up 1.25% on the day. Divis Laboratories Ltd is up 6.81% in last one year as compared to a 4.17% fall in NIFTY and a 15.39% fall in the Nifty Pharma index.The PE of the stock is 71.64 based on TTM earnings ending March 26.Powered by Capital Market - Live

Divis Laboratories announced that the 36th Annual General Meeting(AGM) of the company will be held on 10 August 2026.

Divis Laboratories announced that the Board of Directors of the Company at its meeting held on 23 May 2026, inter alia, have recommended the final dividend of Rs 30 per equity Share (i.e. 1500%) , subject to the approval of the shareholders.

Revenue from operations grew 9.52% YoY to Rs 2,831 crore in Q4 FY26 versus Rs 2,585 crore in Q4 FY25. Profit before tax (PBT) stood at Rs 963 crore, up 11.46% YoY from Rs 864 crore in the corresponding period last year. Total expenses rose 11.95% YoY to Rs 2,023 crore in Q4 FY26, with the cost of materials at Rs 1,214 crore (up 30.4% YoY) and employee benefit expenses at Rs 381 crore (up 8.86% YoY) during the period under review. The company reported a forex gain of Rs 90 crore in Q4 FY26 as against a forex gains of Rs 10 crore for the corresponding quarter of the previous year. On a full-year basis, the company's consolidated net profit rose 17.21% to Rs 2,568 crore on a 12.82% rise in revenue to Rs 10,560 crore in FY26 over FY25. The company's board has recommended a final dividend of Rs 30 per equity share of face value Rs 2 (1,500%) for FY26, subject to shareholder approval at the 36th AGM. The AGM will be held on 10 August 2026, with 24 July 2026 as the record date for dividend eligibility. Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates, and nutraceutical ingredients. Shares of Divis Laboratories rose 0.36% to settle at Rs 6,885 on 22 May 2026.Powered by Capital Market - Live

Net profit of Divi's Laboratories rose 13.44% to Rs 751.00 crore in the quarter ended March 2026 as against Rs 662.00 crore during the previous quarter ended March 2025. Sales rose 9.52% to Rs 2831.00 crore in the quarter ended March 2026 as against Rs 2585.00 crore during the previous quarter ended March 2025. For the full year,net profit rose 17.21% to Rs 2568.00 crore in the year ended March 2026 as against Rs 2191.00 crore during the previous year ended March 2025. Sales rose 12.82% to Rs 10560.00 crore in the year ended March 2026 as against Rs 9360.00 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales2831.002585.00 10 10560.009360.00 13 OPM %32.9934.27 -32.5931.71 - PBDT1083.00971.00 12 3925.003318.00 18 PBT963.00864.00 11 3462.002916.00 19 NP751.00662.00 13 2568.002191.00 17 Powered by Capital Market - Live